A detailed history of J.Safra Asset Management Corp transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 11 shares of VKTX stock, worth $365. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11
Holding current value
$365
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 28, 2025

BUY
$19.98 - $29.49 $219 - $324
11 New
11 $0

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $2.55B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track J.Safra Asset Management Corp Portfolio

Follow J.Safra Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J.Safra Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on J.Safra Asset Management Corp with notifications on news.